Prenetics stock climbed 3.3% in pre-open trading following the company’s release of its Q2 FY2026 financials ahead of the market open. The quarter produced $46.5 million in total revenue, a near-tripling versus the same period a year earlier, and landed within the company’s own guidance range of $46–$48 million.
The IM8 wellness brand emerged as the dominant contributor to the quarter’s performance, producing $45.0 million of revenue and registering approximately 359% growth year-over-year. That result extended IM8’s streak to six straight record quarters, underlining the brand’s centrality to the company’s near-term topline trajectory.
Management highlighted two further disclosures that drew investor attention. July was cited as IM8’s single strongest month on record, generating $20.9 million in revenue. In addition, consolidated Adjusted Free Cash Flow turned positive for the first time - a milestone CEO Danny Yeung described as "the single most important milestone we have been tracking since before the brand launched." Both developments reinforced the operational progress signaled by the headline revenue number.
Alongside the quarterly figures Prenetics adjusted its outlook, raising full-year FY2026 total revenue guidance to a range of $220–$230 million. The company also provided initial FY2027 guidance for IM8, setting a target of $400 million or more in IM8 revenue and explicitly noting that this figure assumes no contribution from forthcoming product launches.
Market context amplified the significance of the results. The pre-market advance came despite a weaker overall market backdrop - with the Nasdaq Composite down 1.3% and the S&P 500 off 0.5% as investors weighed geopolitical tensions and higher oil prices. That Prenetics could stage a pre-market gain in that environment pointed to the earnings and cash flow disclosures being received as a genuine positive surprise by investors.
Taken together, the company’s clean beat inside guidance, a record July for IM8, the first positive consolidated adjusted free cash flow, and an aggressive upward revision of near- and medium-term revenue targets provided several concrete reasons for investor buying interest. In pre-market trading those drivers pushed the stock toward $20.01, placing it within sight of its 52-week high of $23.63.